TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04274946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Description: Sentinel lymph node biopsy(SLNB) procedure with different mapping methods using combination of radioactive colloid, patent blue, indocyanine green associated with intraoperative ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel lymph node biopsy
Description: Sentinel lymph node biopsy(SLNB) procedure with different mapping methods using combination of radioactive colloid, patent blue, indocyanine green associated with intraoperative ultrasound.
Study: NCT06143904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-112638
Description: Pharmaceutical form:Solution-Route of administration:IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-112638
Description: Pharmaceutical form:Solution-Route of administration:IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-112638
Description: Pharmaceutical form:Capsule-Route of administration:Oral
Study: NCT04634500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin Tablet
Study: NCT04401176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin & Alkalinized Lidocaine Bladder Instillation
Description: Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
Study: NCT06143904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-112638
Description: Pharmaceutical form:Capsule-Route of administration:Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Genz-112638
Description: Pharmaceutical form:Solution-Route of administration:Oral
Study: NCT03091348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone cypionate injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone cypionate injection
Study: NCT04401176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onabotulinum Toxin A
Description: Intradetrusor onabotulinumtoxinA injection (0.5mL x 20 sites)
Study: NCT01648127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion
Study: NCT03892304

Intervention type: OTHER
Intervention: Self-report written questionnaire
Description: Patient questionnaire filled-out in presence of clinical nurse. Gynecological options and contraceptive choices were recorded. Close-ended questions used (yes/no): contraception use; contraceptive pill use; contraceptive implant; intrauterine device; tubal sterilization; mechanical contraception; other type of contraception use; previous term delivery; gynecological follow-up; previous Pap smear. If Yes was noted, more details were requested (contraception name, delivery date, gynecological follow-up frequency, last Pap smear date).~Other gynecological history and management data not included in the 2014 questionnaire: age at first menstruation, menstrual cycle regularity without hormonal contraception, age at menopause, previous human papilloma virus vaccination, recurrent vulvovaginal candidiasis, urinary incontinence, fertility/infertility data, and infertility treatment with assisted reproductive technologies. Results were compared with those obtained in 2014 (121 women).
Study: NCT01716403

Intervention type: BIOLOGICAL
Intervention: Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition
Study: NCT03617328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
Study: NCT03652662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESP-FIT
Description: Inspiratory and Expiratory muscle strength training 5 times a week, plus Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RESP-FIT Comparator
Description: Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
Study: NCT03617328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyICLC
Description: polyICLC, local adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyICLC
Description: polyICLC, local adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1127
Description: CDX-1127, anti-CD27 monoclonal antibody
Study: NCT02469870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism Parent Trainer (APT)
Description: Experimental condition

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teaching Routines (Control)
Description: Content comparison group.
Study: NCT06517485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: upifitamab rilsodotin
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: upifitamab rilsodotin
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536
Study: NCT01614483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yellow cassava
Description: Daily provision of 375 g boiled yellow cassava for 18 weeks, 6 days/week Daily provision of placebo capsule for 18 weeks, 6 days/week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White cassava
Description: Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/ week Daily provision of placebo capsule for 18 weeks, 6 days/ week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White cassava
Description: Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/week Daily provision of B-carotene capsule (1400 µg B-carotene)
Study: NCT04514380

Intervention type: OTHER
Intervention: Carbohydrate fluid
Description: 400 mL carbohydrate fluid
Study: NCT02337400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral smoking reduction program Smoke_less
Description: Duration: 5 weeks, 4 sessions over 2,5 hours and 2 phone calls

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 15 minute counseling interview
Study: NCT01988064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face training
Description: One-to-one face-to-face training on calculating the pulse rate and detecting abnormalities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group training
Description: Group training using a tutorial film on calculating the pulse rate and detecting abnormalities.
Study: NCT01308970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Group 1
Description: Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Group 2
Description: Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
Study: NCT04514380

Intervention type: OTHER
Intervention: Non-carbohydrate fluid
Description: 0 mL carbohydrate fluid
Study: NCT01929811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin: 500mg tid, orally (500mg daily in first cycle) on day 1 to day 21 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
Study: NCT01308970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Group 3
Description: Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
Study: NCT01929811

Intervention type: DRUG
Group type: OTHER
Intervention: Epirubicin
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphomide
Description: 500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
Study: NCT03171207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lite Run Gait Trainer
Description: The Lite Run Gait Trainer is a novel device with pneumatic pants that can be used to assist with body support assisted gait therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lite Run Gait Trainer
Description: The Lite Run Gait Trainer is a novel device with pneumatic pants that can be used to assist with body support assisted gait therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Current Harness System
Description: There are a variety of harness systems (e.g., ceiling lift, Lite Gait) that are currently used to assist with body support assisted gait therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Current Harness System
Description: There are a variety of harness systems (e.g., ceiling lift, Lite Gait) that are currently used to assist with body support assisted gait therapy.
Study: NCT01929811

Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphomide
Description: 500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
Study: NCT02436837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sessions with virtual reality
Description: sessions with virtual reality to improve the balance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sessions with virtual reality
Description: sessions with virtual reality to improve the balance
Study: NCT04254913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Suspension
Study: NCT03412240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induced pacing of the heart
Description: Once the defibrillator leads have been inserted or, in the case of a box change, the old leads have been tested as per routine procedure, these pacing leads will be connected to an external pacing stimulator. The test involves electrically pacing your heart at different rates and we will be constantly monitoring you under close clinical supervision. During the test, your heart will be electrically stimulated to beat at a faster rate.
Study: NCT02690311

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: smartphone display
Study: NCT02685137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stannsoporfin
Description: Intramuscular injection of stannsoporfin to treat jaundice.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: nothing
Study: NCT03535298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Highly Effective Therapies Group
Description: Highly Effective MS Therapy group of medications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escalation Therapies Group
Description: Escalation MS Therapy group of medications
Study: NCT05170880

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary endodontic treatment
Description: Primary non surgical endodontic treatment will be provided to patients in treatment group.
Study: NCT01032889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study: NCT01236976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therastride Treadmill System
Description: This device supports spinal cord injured patients to stand (suspended in a harness by an overhead pulley) on the specially designed treadmill for locomotor training. It is registered with the FDA (Regulation Number 890.5380).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES-assisted cycling
Description: This intervention will be provided using a RT300 cycle (Restorative Therapies, Baltimore MD).
Study: NCT02690311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone display
Study: NCT02500121

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT01236976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk and upper and lower limb exercises
Description: This intervention will comprise assisted and/or resisted movements aimed at facilitating and strengthening voluntary muscle activity and improving movement quality.

Intervention type: OTHER
Group type: OTHER
Intervention: Upper body strength and fitness program
Description: This intervention is a circuit-based exercise program incorporating resistance and cardiovascular training.
Study: NCT03308721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-1177 A 1.0 mg/mL
Description: Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.~Dose gradually increased to 6000 μg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.
Study: NCT04370119

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal swab
Description: SARS-CoV-2 PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal swab
Description: SARS-CoV-2 PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal swab
Description: SARS-CoV-2 PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum testing
Description: Anti-SARS-CoV2 S protein IgG ELISA, serological changes after SARS-CoV-2 vaccination

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum testing
Description: Anti-SARS-CoV2 S protein IgG ELISA, serological changes after SARS-CoV-2 vaccination
Study: NCT02500121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or for up to 24 months
Study: NCT04370119

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum testing
Description: Anti-SARS-CoV2 S protein IgG ELISA, serological changes after SARS-CoV-2 vaccination
Study: NCT02949895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study: NCT03651024

Intervention type: DEVICE
Group type: OTHER
Intervention: ED surgery
Description: The surgical implant for ED treatment
Study: NCT05512546

Intervention type: DRUG
Intervention: Aspir-Low Pill
Description: patients were prescribed 75 mg/day of either aspirin

Intervention type: DRUG
Intervention: Aspir-Low Pill
Description: patients were prescribed 75 mg/day of either aspirin
Study: NCT00829192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide (CUV1647)
Description: 16 mg subcutaneous implant administered every 60 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous implant administered every 60 days
Study: NCT01483417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single incision Laparoscopic hysterectomy
Description: SILS port

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic hysterectomy
Description: 3-4 conventional ports
Study: NCT03064737

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsy for genetic analyze
Description: It will be offered to a subgroup of adult patients carrying genetic markers predisposing to the severity of the LD infection, a skin biopsy in order to realize genetic analyses.~This visit will be conducted once the results of genetic markers obtained (between 30 and 36 months), a specific consent will be required to patients.~The skin biopsy will be performed according to the Clinical Department use.
Study: NCT03111446

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Spinal needle 25G with Quincke's bevel will be used. It will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 20 mcg fentanyl (total volume 2.4 ml) at the L3-4 interspace. The parturient will be returned to the supine position with a left lateral tilt of 15° to facilitate left uterine displacement. The upper sensory block level will be checked 5 min after the spinal injection by assessing the loss of cold sensation from alcohol swabs, to ensure that a Th6 sensory block level has been achieved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Pre-oxygenation with oxygen 100% via a tight fitting mask rapid sequence technique. Induction is by thiopental (5 mg kg lean body weight) and succinylcholine1.5 mg kg body weight), cricoid pressure should be applied before consciousness is lost and kept in place until confirmation of tracheal intubation with capnography and the cuff of the tracheal tube is inflated. Auscultating the chest helps exclude endobronchial intubation. At this point, surgery may commence.
Study: NCT01035411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 2 x 30 mg batch DLE494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 2 x 30 mg batch DLF497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 2 x 30 mg tablet variant 1
Study: NCT02512835

Intervention type: OTHER
Intervention: Community vital signs
Description: We will present clinicians with information about their patients' communities
Study: NCT04589026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosentyx
Description: Cosentyx injection will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candin
Description: Candin will be administered interadermally along with NaCl solution.
Study: NCT02678390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT
Description: A 5 day consecutive MCT intake of 30 g/day.
Study: NCT02396472

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Order by time and topic

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Order by information relevance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Order by social relationship

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Order by help giving

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Order by self-disclosure
Study: NCT04240132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence to Hand Hygiene
Description: determine the colonization of microorganisms due to microbial reproduction on the external surface of the distal end of the enteral feeding tube (EFT), hub of the EFT and other feeding system components and assess the relation between the colonization and adherence to hand hygiene practices by nurses and other healthcare workers
Study: NCT02678390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT
Description: A 5 day consecutive MCT intake of 30 g/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT+ aerobic exercise
Description: A 5 day consecutive MCT intake of 30 g/day in combinaison with 30 minutes of aerobic exercise (70% to 80% HRR) per day for the five days.
Study: NCT03601117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dorsolateral Prefrontal Cortex Accelerated Theta Burst Stimulation
Description: Participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC.~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Cingulate Cortex Accelerated Theta Burst Stimulation
Description: Participants will receive iTBS (intermittent theta burst stimulation) to the anterior cingulate cortex (ACC).~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system.
Study: NCT02678390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT+ aerobic exercise
Description: A 5 day consecutive MCT intake of 30 g/day in combinaison with 30 minutes of aerobic exercise (70% to 80% HRR) per day for the five days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: A single period of 30 minutes of aerobic exercise (70% to 80% HRR).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: A single period of 30 minutes of aerobic exercise (70% to 80% HRR).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control day
Description: No MCT or aerobic exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control day
Description: No MCT or aerobic exercise
Study: NCT00773318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT/CT guided LM/SL
Description: Detection, localization, and removal of sentinel lymph node (s) from prostate cancer guided by an integrated SPECT/low-dose multislice CT
Study: NCT04194255

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate
Description: iron (100 mg) supplement in form of ferrous fumarate
Study: NCT01761240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-066
Description: MORAb-066 infusion.